Mikael Landén
Institute of Clinical Neuroscience
Department of Psychiatry
Göteborg University
Sweden
Name/email consistency: high
- A model to explain the therapeutic effects of serotonin reuptake inhibitors: the role of 5-HT2 receptors. Landén, M., Thase, M.E. Psychopharmacol. Bull (2006)
- Dyslipidemia and high waist-hip ratio in women with self-reported social anxiety. Landén, M., Baghaei, F., Rosmond, R., Holm, G., Björntorp, P., Eriksson, E. Psychoneuroendocrinology (2004)
- How does premenstrual dysphoric disorder relate to depression and anxiety disorders?. Landén, M., Eriksson, E. Depress. Anxiety (2003)
- Reduction of the synaptophysin level but normal levels of glycerophospholipids in the gyrus cinguli in schizophrenia. Landén, M., Davidsson, P., Gottfries, C.G., Månsson, J.E., Blennow, K. Schizophr. Res. (2002)
- Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Landén, M., Eriksson, O., Sundblad, C., Andersch, B., Naessén, T., Eriksson, E. Psychopharmacology (Berl.) (2001)
- Attitudes toward transsexualism in a Swedish national survey. Landén, M., Innala, S. Arch. Sex. Behav (2000)
- Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. Landén, M., Eriksson, E., Agren, H., Fahlén, T. J. Clin. Psychopharmacol (1999)
- Reduction of chromogranin A and B but not C in the cerebrospinal fluid in subjects with schizophrenia. Landén, M., Grenfeldt, B., Davidsson, P., Stridsberg, M., Regland, B., Gottfries, C.G., Blennow, K. Eur. Neuropsychopharmacol (1999)